Adverse Effects

Biomarkers

Bladder Cancer

Brain Cancer

HER2-Positive Breast Cancer

Triple-Negative Breast Cancer

Breast Cancer

Cervical Cancer

Colorectal Cancer

Endometrial Cancer

Esophageal Cancer

Gastric Cancer

Gastrointestinal Cancer

Genitourinary Cancers

Gynecologic Cancers

Head & Neck Cancer

Myelodysplastic Syndromes

Myeloproliferative Neoplasms

Hematology

Hormone-related Cancers

Immunotherapy

Vaccines

Infection

Kidney Cancer

Chronic Lymphocytic Leukemia

Acute Lymphoblastic Leukemia

Acute Myeloid Leukemia

Chronic Myeloid Leukemia

Leukemia

Liver Cancer

Lung Cancer

Non-Hodgkin Lymphoma

Diffuse Large B-Cell Lymphoma

Follicular Lymphoma

Hodgkin Lymphoma

Mantle Cell Lymphoma

Marginal Zone Lymphoma

Lymphoma

Melanoma

Mesothelioma

Multiple Myeloma

Neuroendocrine Tumors

Non-Small Cell Lung Cancer (NSCLC)

Oncology

Ovarian Cancer

Ovarian Cancer Clincal Consult

Pancreatic Cancer

Pediatric Cancers

Prostate Cancer

Radiation Oncology

Sarcoma

Screening

Skin Cancer & Melanoma

Small Cell Lung Cancer (SCLC)

Surgery

Thoracic Malignancies 

Thyroid Cancer

News

Clinical Topics

Integrative Care

Global Bulletin

All News

Approval Alert

Media

2 Minute Drill

Around the Practice

Between the Lines

Clinical Consult

Expert Interviews

Face Off

Medical World News

Morning Rounds

OncView

Podcasts

Readout 360

Satellite Sessions

Training Academy

Year in Review

Conferences

Publications

All Journals

Editorial Board

For Authors

Events

Frontline Forum

CME/CE

Resources

Contemporary Concepts

Awareness Month

Interactive Tools

Nurse Practitioners/Physician's Assistants

Partners

Subscribe

Print Subscription

eNewsletter

Hayley Virgil is a senior editor with CancerNetwork. When she isn't traveling to conferences and championing health equity in the oncology space, she can be found hiking, foraging wild plants, gardening, sewing ballgowns, practicing embroidery, or playing video games.

Articles

Second-line treatment with belantamab mafodotin plus bortezomib/dexamethasone in patients with relapsed/refractory multiple myeloma is supported by findings from the phase 3 DREAMM-7 study.

Belantamab Mafodotin Improves PFS in Relapsed/Refractory Multiple Myeloma

Russ Conroy is an Assistant Editor for CancerNetwork. He grew up in Hillsborough, New Jersey, and graduated from Rutgers University-New Brunswick in 2022. 

On the weekends, he likes to unwind by playing video games with friends, tailgating at Rutgers football games with his family, or building his music collection with a visit to Princeton Record Exchange.

Patients with desmoid tumors can now receive nirogacestat following the FDA’s approval of the agent.

FDA OKs Nirogacestat for Treatment of Desmoid Tumors

Safety data from the phase 3 PREVAPIX-ALL trial support the use of apixaban among pediatric patients with acute lymphoblastic leukemia who are at high risk of thrombosis.

Apixaban Yields No Significant Benefit in Acute Lymphoblastic Leukemia 

Total costs for endometrial cancer therapy in the first line appear to be higher for those diagnosed with metastatic disease compared with those who do not have metastatic disease.

Frontline Advanced Endometrial Cancer Therapy Confers High Economic Burden

Home to the journal Oncology, Cancer Network provides research and opinion on the screening, early detection, diagnosis, treatment, and prevention of cancers.

About

Advertise

CureToday.com

OncLive.com

OncNursingNews.com

TargetedOnc.com

Contact

Terms and Conditions

Privacy

Do Not Sell My Personal Information

Cancer Network

Facebook

LinkedIn

Twitter

Spotlight

Around the Practice 

Insights from Experts at Mayo Clinic on Translating Evidence to Clinical Practice

Poll | Resources